Azenta (NASDAQ:AZTA – Get Free Report) and Champions Oncology (NASDAQ:CSBR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.
Volatility and Risk
Azenta has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.
Profitability
This table compares Azenta and Champions Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Azenta | -20.63% | 1.18% | 0.97% |
| Champions Oncology | -1.82% | -26.13% | -3.87% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Azenta | 1 | 2 | 4 | 0 | 2.43 |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
Azenta presently has a consensus target price of $41.20, suggesting a potential upside of 33.55%. Given Azenta’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Azenta is more favorable than Champions Oncology.
Earnings & Valuation
This table compares Azenta and Champions Oncology”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Azenta | $593.82 million | 2.28 | -$55.76 million | ($2.76) | -11.18 |
| Champions Oncology | $59.42 million | 1.17 | -$1.17 million | ($0.08) | -62.45 |
Champions Oncology has lower revenue, but higher earnings than Azenta. Champions Oncology is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
99.1% of Azenta shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 10.9% of Azenta shares are held by insiders. Comparatively, 46.3% of Champions Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Azenta beats Champions Oncology on 10 of the 14 factors compared between the two stocks.
About Azenta
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
About Champions Oncology
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
